Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

NCT07351786 is registered in ClinicalTrials.gov with Sara A Belal as lead sponsor.

NCT NCT07351786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07351786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
Lead sponsor
Sara A Belal
Phase
Observational
Overall status
Recruiting
Start date
August 1, 2025
Completion date
September 30, 2026
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes (dm), diabetic retinopathy (dr), diabetic retinopathy associated with type 2 diabetes mellitus, retinopathy, diabetic